JP2020505418A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505418A5 JP2020505418A5 JP2019541246A JP2019541246A JP2020505418A5 JP 2020505418 A5 JP2020505418 A5 JP 2020505418A5 JP 2019541246 A JP2019541246 A JP 2019541246A JP 2019541246 A JP2019541246 A JP 2019541246A JP 2020505418 A5 JP2020505418 A5 JP 2020505418A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- use according
- pathogen
- binding protein
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 44
- 108091008324 binding proteins Proteins 0.000 claims description 18
- 244000052769 pathogen Species 0.000 claims description 18
- 230000001717 pathogenic effect Effects 0.000 claims description 18
- 239000012642 immune effector Substances 0.000 claims description 10
- 229940121354 immunomodulator Drugs 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 8
- 244000309459 oncolytic virus Species 0.000 claims description 7
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 6
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 6
- 241000700584 Simplexvirus Species 0.000 claims description 5
- 241000701022 Cytomegalovirus Species 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 101000807236 Human cytomegalovirus (strain AD169) Membrane glycoprotein US3 Proteins 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 102100022427 Plasmalemma vesicle-associated protein Human genes 0.000 claims description 3
- 101710193105 Plasmalemma vesicle-associated protein Proteins 0.000 claims description 3
- 101710145727 Viral Fc-gamma receptor-like protein UL119 Proteins 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 229940027941 immunoglobulin g Drugs 0.000 claims 12
- 102000023732 binding proteins Human genes 0.000 claims 8
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 2
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000000174 oncolytic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 11
- 102000014914 Carrier Proteins Human genes 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 230000001900 immune effect Effects 0.000 description 6
- 208000037952 HSV-1 infection Diseases 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 3
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 102000009490 IgG Receptors Human genes 0.000 description 2
- 108010073807 IgG Receptors Proteins 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 238000011394 anticancer treatment Methods 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229940125645 monoclonal antibody drug Drugs 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762452111P | 2017-01-30 | 2017-01-30 | |
| US62/452,111 | 2017-01-30 | ||
| PCT/US2018/016035 WO2018140974A1 (en) | 2017-01-30 | 2018-01-30 | Passive antibody dependent cell-mediated activation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020505418A JP2020505418A (ja) | 2020-02-20 |
| JP2020505418A5 true JP2020505418A5 (enExample) | 2021-03-11 |
Family
ID=62979661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541246A Pending JP2020505418A (ja) | 2017-01-30 | 2018-01-30 | 受動抗体依存性細胞媒介活性化 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11459378B2 (enExample) |
| EP (1) | EP3573640A4 (enExample) |
| JP (1) | JP2020505418A (enExample) |
| CN (1) | CN110536699A (enExample) |
| AU (1) | AU2018213418A1 (enExample) |
| WO (1) | WO2018140974A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020530454A (ja) | 2017-08-07 | 2020-10-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 安全な細胞治療薬を生成するためのプラットフォーム |
| JP2022542032A (ja) * | 2019-07-21 | 2022-09-29 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 治療用ウイルスワクチン |
| CN111411079B (zh) * | 2020-03-27 | 2025-12-12 | 北京时合生物科技有限公司 | 细胞培养方法、改造抗体、细胞培养基、细胞产品及其应用 |
| CN114621356A (zh) * | 2022-05-17 | 2022-06-14 | 康希诺生物股份公司 | 以il18为分子佐剂的带状疱疹亚单位疫苗 |
| WO2024086400A1 (en) * | 2022-10-17 | 2024-04-25 | Research Institute At Nationwide Children's Hospital | Macrophage polarizing oncolytic herpes simplex virus for cancer therapy |
| WO2024254444A1 (en) * | 2023-06-09 | 2024-12-12 | Cornell University | Vaccines for human cytomegalovirus |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2573114B1 (en) | 2005-08-10 | 2016-03-30 | MacroGenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US9758794B2 (en) * | 2008-04-22 | 2017-09-12 | Rutgers, The State University Of New Jersey | HCV E2 construct compositions and methods |
| CA2781539C (en) * | 2009-11-23 | 2021-07-20 | Amgen Inc. | Monomeric antibody fc |
| EP2603526A1 (en) * | 2010-08-13 | 2013-06-19 | Medimmune Limited | Monomeric polypeptides comprising variant fc regions and methods of use |
| GB201013989D0 (en) * | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
| WO2013138643A1 (en) * | 2012-03-16 | 2013-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Soluble engineered monomeric fc |
| CN105669838B (zh) | 2014-12-04 | 2020-10-16 | 厦门大学 | 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体 |
-
2018
- 2018-01-30 US US16/480,293 patent/US11459378B2/en active Active
- 2018-01-30 WO PCT/US2018/016035 patent/WO2018140974A1/en not_active Ceased
- 2018-01-30 AU AU2018213418A patent/AU2018213418A1/en not_active Abandoned
- 2018-01-30 JP JP2019541246A patent/JP2020505418A/ja active Pending
- 2018-01-30 EP EP18744927.7A patent/EP3573640A4/en not_active Withdrawn
- 2018-01-30 CN CN201880007963.0A patent/CN110536699A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505418A5 (enExample) | ||
| Wang et al. | Pathogenesis of herpes stromal keratitis: immune inflammatory response mediated by inflammatory regulators | |
| JP7133241B2 (ja) | Ｉｆｎと抗ｐｄ－ｌ１抗体の融合タンパク質およびその使用 | |
| Lam et al. | NK cells in host responses to viral infections | |
| JP2020055858A5 (enExample) | ||
| JP2019519245A5 (enExample) | ||
| Davignon et al. | Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review | |
| Grebenciucova et al. | Immunosenescence: the role of aging in the predisposition to neuro-infectious complications arising from the treatment of multiple sclerosis | |
| FI3421486T3 (fi) | Uusia vista-ig-rakenteita ja vista-ig:n käyttö autoimmuuni-, allergia- ja tulehdushäiriöiden hoitamiseksi | |
| Jain et al. | Immunotherapy for nasopharyngeal cancer—a review | |
| Jasinski-Bergner et al. | Molecular mechanisms of human herpes viruses inferring with host immune surveillance | |
| Saha et al. | Oncolytic herpes simplex virus interactions with the host immune system | |
| RU2021127872A (ru) | Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов | |
| US20220380468A1 (en) | Modulation of immune response using btla agonist antibodies | |
| Dai et al. | Molecular basis for the recognition of herpes simplex virus type 1 infection by human natural killer cells | |
| RU2020115527A (ru) | Биспецифичные молекулы, иммунореактивные с иммунными эффекторными клетками, экспрессирующими активирующий рецептор | |
| Poddighe et al. | Biologics for the treatment of juvenile idiopathic arthritis | |
| JP2014516026A5 (enExample) | ||
| Dai et al. | The Fc domain of immunoglobulin is sufficient to bridge NK cells with virally infected cells | |
| Lorenzo et al. | APL-1, an altered peptide ligand derived from heat-shock protein, alone or combined with methotrexate attenuates murine collagen-induced arthritis | |
| JP2016538297A5 (enExample) | ||
| CN120392995A (zh) | 利用预先存在的微生物免疫的癌症治疗 | |
| Chowdhury et al. | Amino acid differences in glycoproteins B (gB), C (gC), H (gH) and L (gL) are associated with enhanced herpes simplex virus type-1 (McKrae) entry via the paired immunoglobulin-like type-2 receptor α | |
| Jung et al. | Immune control of oncogenic γ-herpesviruses | |
| Valenzuela-Cardenas et al. | TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy |